Lilly & Co Eli's Net Worth
Estimate Recalculated Dec 3, 2025 08:07PM EST
Who is Lilly & Co Eli
Lilly & Co Eli has an estimated net worth of $1.05 Billion. This is based on reported shares across multiple companies, which include Prevail Therapeutics Inc., Sigilon Therapeutics, Inc., Avidity Biosciences, Inc., Dermira, Inc., Elanco Animal Health Inc, Zymeworks Inc., LEAP THERAPEUTICS, INC., CoLucid Pharmaceuticals, Inc., Aeglea BioTherapeutics, Inc., Coherus BioSciences, Inc., Cerulean Pharma Inc., UNITED THERAPEUTICS Corp, ICAGEN INC, Zosano Pharma Corp, ISIS PHARMACEUTICALS INC, Receptos, Inc., and Akouos, Inc..
SEC CIK
Lilly & Co Eli's CIK is 0000059478
Past Insider Trading and Trends
2010 was Lilly & Co Eli's most active year for acquiring shares with 3 total transactions. Lilly & Co Eli's most active month to acquire stocks was the month of August. 2018 was Lilly & Co Eli's most active year for disposing of shares, totalling 17 transactions. Lilly & Co Eli's most active month to dispose stocks was the month of July. 2017 saw Lilly & Co Eli paying a total of $896,757,522.00 for 19,285,108 shares, this is the most they've acquired in one year. In 2011 Lilly & Co Eli cashed out on 1,050,281 shares for a total of $100,837,022.62, their largest year based on trade value.
Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
